Gyre Therapeutics – A biotechnology company focused on organ fibrosis and inflammatory diseases

Welcome to Gyre Therapeutics

We are a biotechnology company focused on organ fibrosis and inflammatory diseases. Learn more

Our Science

Hydronidone

MASH

Other Disease Areas

Latest news

Mar 27, 2025

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Mar 17, 2025

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Jan 06, 2025

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

More news